The acquisition includes J-Valve, developed by JC Medical, is a minimally invasive transcatheter aortic valve replacement (TAVR) device for both aortic regurgitation and stenosis patients
J-Valve is also designed for patients with low coronary ostium height and small sinuses. (Credit: StockSnap from Pixabay)
Medical device company Genesis MedTech Group has wrapped up the acquisition of structural heart company JC Medical (JCM).
JCM is involved in the designing and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases.
The company has developed a minimally invasive transcatheter aortic valve replacement (TAVR) device, dubbed J-Valve, suitable for both aortic regurgitation and stenosis patients.
J-Valve is said to be the first and only minimally invasive TAVR device approved for both aortic regurgitation and stenosis patients in China.
According to the company, the design of the product helps to reduce stent migration, as well as allows to improve safety and clinical efficacy.
J-Valve is also designed for patients with low coronary ostium height and small sinuses, and the patients requiring aortic and mitral valve-in-valve procedures.
Genesis MedTech Group chairman and CEO Warren Wang said: “The acquisition of JCM and J-Valve exemplifies the type of innovations we envisage as part of a growing Genesis portfolio.
“We are incredibly pleased to start a new Structural Heart Franchise, spearheaded by the best-in-class TAVR solution, J-Valve. By doing this we hope to better support cardiac surgeons and cardiologists in their fight against structural heart diseases.”
J-valve, which includes both transapical (J-Valve TA) and transfemoral (J-Valve TF) TAVR, is claimed to be one of China’s top three most used TAVR by volume alone.
With more than 20 valve implants to date, J-Valve TF is restricted to only compassionate use in the US and Canada.
The J-Valve TF will be fully commercialised in the US, upon completion of clinical trials and securing premarket approval from the US Food and Drug Administration.
JCM founder and president Zhang will continue to serve as president for the company, in addition to acting as CTO for Genesis’ structural heart franchise.